RESISTING studies three different Italian regional contexts.Speakers: Nadia Caruso (Politecnico di Torino), Saskia Gribling (Politecnico di Torino) 247 Governing tactical urbanism
This regulatory situation creates challenges
Precision Matters: The right ratio is key to ensuring accurate and repeatable research results
The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, meaning it cannot be compounded by commercial pharmaceutical companies and there is insufficient evidence regarding potential human harm
The therapeutic window appears well-established at these dosing levels, with higher doses unlikely to provide proportional additional benefits while potentially increasing adverse events
Animal studies have explored its effects on gastric ulcer models, inflammatory bowel conditions, and intestinal anastomosis healing, with researchers observing notable cytoprotective responses in mucosal tissue models